Clinical trial Recruiting at 2 sites Observational Ages 18 to 90

Comparing two neuromuscular monitoring devices during surgery

Official title: Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor:a Pilot Study

Run by Huazhong University of Science and Technology · NCT05632107 · Data updated 2026-11-12

This study is testing a new device that combines two methods for checking muscle function during surgery to see if it works better than a common monitor used today.

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment100 (estimated)
SponsorHuazhong University of Science and Technology
Academic / other
Locations2 sites (Wuhan, Hubei and 1 other locations)
StatusRecruiting
StartedMarch 1, 2023
Main results expectedDecember 2026
Study endsDecember 2027
Registry record updatedApril 3, 2026
Trial IDNCT05632107 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients under 18 years old, classified as ASA Physical Status I to III, and scheduled for elective surgery that requires muscle relaxation.

Probably not a fit

Patients with known neuromuscular disorders, a history of allergic reactions to neuromuscular blocking agents, or those on medications affecting neuromuscular transmission may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a new device that combines acceleromyography (AMG) and electromyography (EMG) for monitoring neuromuscular blockade during elective surgeries. The goal is to determine the validity of this device in accurately assessing neuromuscular function and preventing residual effects after surgery. By comparing it to the widely used TOF-Watch® monitor, the study aims to improve the reliability and ease of neuromuscular monitoring in clinical practice. Participants will include patients undergoing elective surgery requiring muscle relaxation.

Why it matters

Potential benefit: If successful, this study could enhance the safety and effectiveness of neuromuscular monitoring, reducing the risk of complications from residual neuromuscular blockade.

How similar studies have gone: While the use of EMG in neuromuscular monitoring is gaining attention, this specific combination of AMG and EMG has not been previously reported, making this approach novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age less than 18 yr
* American Society of Anesthesiologists Physical Status I to III
* Elective surgery requiring muscle relaxation
* Patients participated voluntarily and signed informed consent

Exclusion Criteria:

* Patients with known neuromuscular disorder
* Stroke
* Patients with a history of allergic reaction toneuromuscular blocking agents
* Use of medications that might interfere with neuromuscular transmission
* Any previous injury to the examined arm that might influence nerve conduction parameters
* Pacemaker

Where it's running

  • Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
  • Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.